Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Interquim SA aggregated by PharmaCompass.com.

    Client Virtual Booth

    INTERQUIM SA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    • Aripiprazole

    • Aripiprazole Lauroxil

    • Ciclopirox

    • Ciclopirox Olamine

    • Edaravone

    • Ferric Carboxymaltose

    • Ferric Derisomaltose

    • Imiquimod

    • Lifitegrast

    • Lumateperone Tosylate

    • Paliperidone

    • Paliperidone Palmitate

    • Rasagiline Tartrate

    • Rivastigmine

    • Rivastigmine Tartrate

    • Roflumilast

    • Rotigotine

    • Tadalafil

    • Tapinarof

    • Tolterodine Tartrate

    SERVICES

    Key Products KEY SERVICES

    • API Process Development

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Full View ScreenFull Screen View
    Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
    Ferrer offers $122M biobucks for ex-US license to Verge ALS drug

    https://www.businesswire.com/news/home/20240325739095/en

    BUSINESSWIRE
    25 Mar 2024
    Share Share
    More than 350 Latin American doctors participate in the second Ferrer Summit in the region
    More than 350 Latin American doctors participate in the second Ferrer Summit in the region

    https://www.ferrer.com/es/Mas-de-350-medicos-latinoamericanos-participan-en-la-segunda-Cumbre-de-Ferrer-en-la-region

    PRESS RELEASE
    23 Oct 2023
    Share Share
    More than 1,200 Ferrer volunteers join in a global commitment to social justice during our Days for Good
    More than 1,200 Ferrer volunteers join in a global commitment to social justice during our Days for Good

    https://www.ferrer.com/es/Mas-de-1200-voluntarios-de-Ferrer-se-unen-en-un-compromiso-global-por-la-justicia-social-durante-nuestros-Days-for-Good

    PRESS RELEASE
    09 Oct 2023
    Share Share
    The World Health Organization includes the cardiovascular polypill developed by the CNIC and Ferrer in the list of essential medicines
    The World Health Organization includes the cardiovascular polypill developed by the CNIC and Ferrer in the list of essential medicines

    https://www.ferrer.com/es/La-Organizacion-Mundial-de-la-Salud-incluye-la7-polipildora-cardiovascular-desarrollada-por-el-CNIC-y-Ferrer-en-la-lista-de-medicamentos-esenciales

    PRESS RELEASE
    01 Aug 2023
    Share Share
    We allocate more than 40% of our profits to social and environmental projects for the third consecutive year
    We allocate more than 40% of our profits to social and environmental projects for the third consecutive year

    https://www.ferrer.com/es/Ferrer-destina-mas-del-40-por-ciento-de-sus-beneficios-a-proyectos-sociales-y-medioambientales-por-tercer-a%C3%B1o-consecutivo

    PRESS RELEASE
    11 Jul 2023
    Share Share
    Ferrer4Future launches an open innovation challenge to promote digital solutions for ALS
    Ferrer4Future launches an open innovation challenge to promote digital solutions for ALS

    https://www.ferrer.com/es/Ferrer4Future-lanza-un-reto-de-innovacion-abierta-para-impulsar-soluciones-digitales-para-la-ELA

    PRESS RELEASE
    21 Jun 2023
    Share Share
    We extend our clinical trial in amyotrophic lateral sclerosis
    We extend our clinical trial in amyotrophic lateral sclerosis

    https://www.ferrer.com/es/Extendemos-nuestro-ensayo-clinico-en-esclerosis-lateral-amiotrofica

    PRESS RELEASE
    21 Jun 2023
    Share Share
    We’ve been awarded EcoVadis GOLD Rating!
    We’ve been awarded EcoVadis GOLD Rating!

    https://www.ferrer.com/web/en/We-ve-been-awarded-EcoVadis-GOLD-Rating

    PRESS RELEASE
    30 Mar 2023
    Share Share
    Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP)
    Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP)

    https://www.ferrer.com/web/en/We-acquire-worldwide-rights-to-ASN90-an-O-GlcNAcase-inhibitor-to-treat-Progressive-Supranuclear-Palsy

    PRESS RELEASE
    22 Feb 2023
    Share Share
    The Bellvitge University Hospital and Ferrer collaborate to promote innovation in the field of health
    The Bellvitge University Hospital and Ferrer collaborate to promote innovation in the field of health

    https://www.ferrer.com/es/El-Hospital-Universitario-de-Bellvitge-y-Ferrer-colaboran-para-promocionar-la-innovacion-en-el-ambito-de-la-salud

    PRESS RELEASE
    21 Feb 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Access Website

    Contact Supplier

    View Presentation

    Interquim 250

    CPhI Japan

    Attending

    envelop Contact Supplier

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search